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ABSTRACT 
Background and Aims: Patients with irritable bowel syndrome (IBS) may pursue 
complementary and alternative medicine (CAM). We conducted a comprehensive systematic 
review and meta-analysis examining efficacy of CAM vs. placebo or sham in adults with IBS. 
Methods: Publication databases were searched for randomized controlled trials of CAM 
therapies (herbal therapy, dietary supplements, mind-body based, body-based, and energy-
healing) in adults with IBS. Data were extracted to obtain pooled estimates of mean 
improvement in abdominal pain (standardized mean difference [SMD]) and relative risk (RR) of 
overall response using random effects models. Sensitivity and subgroup analyses along with 
quality assessments were completed.  
Results: Among 2825 articles identified, 66 were included. Herbal therapy (SMD=0.47, 95% CI: 
0.20 to 0.75, I2=82%) demonstrated significant benefit over placebo for abdominal pain (low 
confidence in estimates). Benefit with mind-body based therapy for abdominal pain was of 
borderline significance (SMD=0.29, 95% CI: -0.01 to 0.59, I2=78%). Herbal therapy (RR=1.57, 
95% CI: 1.31 to 1.88, I2=77%), dietary supplements (RR=1.95, 95% CI: 1.02 to 3.73, I2=75%), 
and mind-body based therapy (RR=1.67, 95% CI: 1.13 to 2.49, I2=63%) showed benefit for 
overall response compared to placebo (low confidence in estimates). Body-based and energy 
healing therapies demonstrated no significant benefit over placebo or sham for abdominal pain or 
overall response. 
Conclusion: CAM therapies such as herbal or dietary supplements and mind-body based 
approaches may be beneficial for abdominal pain and overall response in IBS. However, overall 
quality of evidence is low. Rigorous, high quality clinical trials are warranted to investigate 
CAM in IBS. 
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WHAT YOU NEED TO KNOW 
Background: Many patients with IBS, even those satisfied with traditional therapy, pursue 
complementary alternative medicine (CAM). It is important for clinicians to understand the 
evidence of these therapies when counseling patients. 
Findings: In this systematic review and meta-analysis of randomized controlled trials, specific 
CAM therapies were beneficial for abdominal pain (herbal, mind-body) and overall response in 
IBS (herbal or dietary supplements, mind-body). However, the strength of the evidence is low.  
Implications for care: It is important for clinicians to recognize that CAM could have a role for 
the management of IBS; however, high quality randomized clinical trials should be pursued to 
validate these observations.  
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INTRODUCTION 
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, with an estimated global 
prevalence of 5.8%-17.5%.1 It is associated with significant healthcare and financial burden, as 
well as quality of life consequences. Patients and providers are often unsatisfied with available 
pharmacologic remedies and may seek complementary and alternative medicine (CAM),2 a 
unique and holistic approach to treatment that is not a typical component of conventional 
medicine. CAM therapies are also sought out by patients who are satisfied with conventional 
therapy3 and to supplement conventional treatment options4. It is important for physicians to 
understand the evidence behind CAM in order to appropriately counsel patients on their use. 
Studied CAM therapies include herbal remedies, dietary supplements, mind-body based 
interventions, body-based interventions, and energy-healing therapies. To clarify the clinical 
utility of CAM for management of IBS, critical assessment of the available evidence that exists 
on this topic is required.  
Although several systematic reviews and meta-analyses on specific CAM therapies have 
been performed, outcome assessments have been limited and comparisons have generally been 
made to Western approaches, pharmacological therapies, wait-list controls or usual care which 
may contribute to uncertain estimates of efficacy. A previous systematic review investigating 
placebo response in CAM trials in IBS reported a pooled estimate of the placebo response rate to 
be 42.6%, demonstrating the importance of considering placebo effects and methodological rigor 
of clinical CAM trials in IBS5. Studies assessing specific CAM therapies include a recently 
published systematic review and network meta-analyses that found needle acupuncture plus 
Geshanxiaoyao formula and moxibustion to be associated with the highest probabilities of 
improving global IBS symptoms6. However, other patient-reported outcomes such as individual 
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symptoms (e.g. abdominal pain) were not assessed. Other carefully conducted reviews including 
network meta-analyses have reported benefit with psychological therapies in IBS, but the 
majority of included studies had no placebo or sham comparison leading to concerns for possible 
overestimation of treatment effects7, 8. Meanwhile, a 2016 systematic review and meta-analysis9 
of randomized controlled trials (RCTs) of Chinese herbal medicine for diarrhea-predominant IBS 
found significant improvement in overall symptoms, diarrhea, and abdominal pain, but was 
restricted by small patient numbers and a limited bias assessment.  
Our aim was to conduct an updated and comprehensive systematic review and meta-
analysis examining the efficacy of CAM therapies including herbal and dietary supplements, 
mind-body based intervention, body-based methods, and energy-based healing therapies vs. 
placebo or sham therapy for the clinical efficacy endpoints of abdominal pain and overall 
response in patients with IBS. 
METHODS 
A systematic review and meta-analysis was conducted in accordance with the PRISMA-P 
statement to provide detailed, transparent reporting10. The study protocol was published on 
PROSPERO (registration number CRD42018108040). Endnote X9 and Microsoft Excel were 
used to manage data. 
Search strategy and study selection: A search of Ovid MEDLINE,  Embase, and PsycINFO for 
randomized, placebo- or sham-controlled trials of CAM therapies in adults with IBS through 
June 2020 was conducted by a librarian (HC) and was adapted from the Scottish Intercollegiate 
Guidelines Network.11 Bibliographies of relevant papers were reviewed. There were no language 
or date limitations. A list of search terms can be found in the Supplement. 
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RCTs comparing CAM to placebo or sham for abdominal pain and/or overall response in 
adults with IBS were eligible. Details on study eligibility criteria are included in the 
Supplemental Methods. CAM therapies included herbal and dietary supplements, mind-body 
based therapies, body-based therapies, and energy-based therapies. Two reviewers (WB and 
KM) independently reviewed titles and abstracts identify potentially relevant articles for full text 
review. Agreement was evaluated using the kappa statistic.12 Both reviewers reviewed full text 
articles in detail. Disagreements were harmonized by consensus or by a third party when 
required (AS).  
Study Outcomes: Primary outcomes were the effect of CAM-based therapy compared to 
placebo or sham on (1) mean improvement in abdominal pain (continuous variable), consistent 
with the Food and Drug Administration’s (FDA) guidance on clinical endpoints for IBS trials,13 
and (2) efficacy according to overall response as defined by each study protocol (dichotomous 
variable). Frequency and types of adverse events were also analyzed. 
Data Extraction: Data extraction was performed independently (WB and KM). Clinical data 
extracted from each trial included study participant characteristics, interventions, control type, 
duration of therapy, and outcomes. For abdominal pain, data were extracted as mean change in 
abdominal pain severity. When mean improvement was not reported or could not be calculated, 
we extracted the mean or median values for post-treatment score.14 Proxy scores for abdominal 
pain (e.g. overall symptom severity score) were used when not directly reported or provided by 
authors. For overall response, data were extracted as dichotomous outcomes, defined as the 
proportion of patients achieving the pre-specified study endpoint of response. Data were 
extracted as intention-to-treat analyses, using all available data for continuous outcomes and 
assuming drop-outs to be non-responders for dichotomous outcomes. Discrepancies were settled 
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by a third independent author (AS). For studies involving multiple treatment arms compared to 
one control arm, treatment arms were combined for an overall treatment effect when appropriate 
(i.e. when multiple doses of the same therapy were used). Authors of studies with incomplete 
data were contacted via email to obtain the necessary information. 
Quality of evidence: The Grading of Recommendations Assessment, Developmnt and 
Evaluation (GRADE) approach was used to assess the methodological quality of included RCTs 
as well as the strength of the body of evidence.15  
Data synthesis and statistical analysis: Meta-analytic estimates of treatment effect were 
expressed as standardized mean difference (SMD) for improvement in abdominal pain severity 
and relative risk (RR) for overall response. The random effects model was used due to known 
clinical and methodologic heterogeneity of studies (different CAM treatments). Heterogeneity 
was assessed using the Higgins and Thompson I2 statistic and its associated confidence 
interval16. To investigate potential sources of heterogeneity, subgroup and meta-regression 
analyses were performed by intervention type, risk of bias, location, IBS definition, IBS type, 
IBS severity, proportion of female subjects and placebo response rates when possible. 
Publication bias was evaluated using funnel plots and Egger’s test. When there was significant 
heterogeneity, a Baujat plot was used to detect of outliers.17 Sensitivity analyses were performed 
after excluding these articles. Number needed to treat (NNT) values were calculated using the 
formula NNT (1/[control event rate×(1−RR)]). All anlyses were performed using R version 
3.6.1 (R Foundation for Statistical Computing).18 Statistical tests were 2-sided with a 
significance level of 0.05. 
RESULTS 
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The literature search yielded 2825 distinct articles, of which 220 were retrieved for full text 
review. Agreement between authors was almost perfect (kappa statistic = 0.90). Of the 220 
articles reviewed in detail, 66 articles comprising 6764 total participants were included (Figure 
1) in the final analysis19-84. Three studies31, 37, 38 examined more than one intervention compared 
to separate control arms and were included separately. Study characteristics are shown in Table 
1. Risk of bias assessments are shown in Supplementary Table 1. GRADE assessments for each 
outcome and for each therapy class are included in Table 2. Results of subgroup analyses not 
shown in the main manuscript are included in Supplementary Table 2. 
Efficacy of body-based therapy: Data on the efficacy of body-based therapy for abdominal 
pain were analyzed from 7 papers containing 8 RCTs evaluating 308 patients. There were no 
significant differences in abdominal pain between body-based therapy and placebo with low 
heterogeneity (SMD=-0.04, 95% CI: -0.36 to 0.28, I2=12%, [Supplementary Figure 1]) and low 
confidence in estimates. All but one study22 evaluated relaxation therapy. Excluding this study 
did not change results (SMD=-0.08, 95% CI: -0.45 to 0.29). There were no subgroup differences 
by risk of bias and no significant publication bias (p=0.46). 
Data on efficacy of body-based therapy for overall response in IBS were available in 5 
papers containing 6 RCTs evaluating 270 patients. Pooled analysis demonstrated no difference in 
overall response between body-based therapy and placebo with moderate heterogeneity 
(RR=1.32, 95% CI: 0.89 to 1.95, I2=40%, [Supplementary Figure 2]) and low confidence in 
estimates. Three studies31, 42, 72 were large contributors to heterogeneity and exclusion reduced 
heterogeneity (I2=22%) without changing treatment effect (RR=1.49, 95% CI: 0.96 to 2.31). 
Exclusion of the only study42 that did not use a relaxation intervention demonstrated similar 
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findings (RR=1.16, 95% CI: 0.76 to 1.78, I2=4%). There were no subgroup differences by risk of 
bias and no significant publication bias (p=0.69). 
 
Efficacy of dietary supplements: Data on the efficacy of dietary supplements for abdominal 
pain were analyzed from 15 papers containing 15 RCTs evaluating 939 patients. Pooled analysis 
demonstrated no significant difference between dietary supplements and placebo with 
considerable heterogeneity (SMD=0.13, 95% CI: -0.26 to 0.51, I2=87%, [Supplementary Figure 
3]) and low confidence in estimates. Exclusion of one outlier study84 improved heterogeneity 
(I2=59%) with no significant change in results (SMD=-0.02, 95% CI: -0.26 to 0.22). There were 
no subgroup differences by intervention type, risk of bias, location, IBS subtype, IBS severity or 
duration of therapy. Meta-regression, excluding theoutlier study, demonstrated a negative 
association between percent females and treatment eff c (p=0.02), but no association between 
placebo response and treatment effect (p=0.14). There was no significant publication bias 
(p=0.57).  
Data on efficacy of dietary supplements for overall esponse in IBS were available in 7 
papers containing 7 RCTs evaluating 432 patients. Dietary supplements were associated with 
benefit compared to placebo in overall response (RR=1.95, 95% CI: 1.02 to 3.73, I2=75%, 
[Supplementary Figure 4]) corresponding to an NNT of 4 (95% CI: 2 to 189) with moderate 
heterogeneity and moderate confidence in estimates. Exclusion of two outliers79, 84 reduced 
heterogeneity (I2=0%) with minimal change in effect (RR=1.86, 95% CI: 1.39 to 2.48). There 
were no subgroup differences by intervention type or risk of bias (both p=ns) and no significant 
publication bias (p=0.37).  
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Efficacy of energy-healing therapy: Data on the efficacy of energy-healing therapy for 
abdominal pain were analyzed from 6 papers containig 6 RCTs evaluating 464 patients. Pooled 
analysis demonstrated no difference compared to placebo with moderate heterogeneity 
(SMD=0.21, 95% CI: -0.20 to 0.61, I2=47%, [Supplementary Figure 5]) and low confidence in 
estimates. Exclusion of one outlier21 educed heterogeneity with no change in effect (SMD=0.12, 
95% CI: -0.13 to 0.37, I2=0%). There were no subgroup differences by intervention type or risk 
of bias (both p=ns) and no significant publication bias (p=0.60). 
Data on efficacy of energy-healing for overall response in IBS were available in 3 papers 
containing 4 RCTs, all of which evaluated acupuncture, in 299 patients. Pooled analysis 
demonstrated no difference between energy-healing ad placebo with low heterogeneity 
(RR=1.32, 95% CI: 0.99 to 1.76, I2=0%, [Supplementary Figure 6]) and low confidence in 
estimates. There was no significant publication bias (p=0.67).  
 
Efficacy of herbal therapies: Data on the efficacy of herbal therapies for abdominal pain were 
analyzed from 17 papers containing 17 RCTs evaluating 2248 patients. Pooled analysis 
demonstrated a significant effect with herbal therapies over placebo with considerable 
heterogeneity (SMD=0.47, 95% CI: 0.20 to 0.75, I2=82%, [Figure 2]) and with low confidence. 
Two studies63, 69 were outliers and exclusion increased treatment effect while reducing 
heterogeneity (SMD=0.61, 95% CI: 0.39 to 0.82, I2=69%). There were no subgroup differences 
by intervention type, risk of bias, location, IBS definition, IBS type, or study duration. Meta-
regression, excluding outliers, demonstrated no significant associations between treatment effect 
and percent females (p=0.34) or placebo response (p=0.99). There was no significant publication 
bias (p=0.97). 
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Data on efficacy of herbal therapies for overall response in IBS were available in 20 
papers containing 20 RCTs evaluating 2833 patients. Herbal therapy was associated with benefit 
over placebo (RR=1.57, 95% CI: 1.31 to 1.88, I2=77%, [Figure 4]), corresponding to an NNT of 
5 (95% CI: 4 to 9) with high heterogeneity and moderat  confidence in estimates. Three 
studies36, 63, 69 were large contributors to heterogeneity and exclusion reduced heterogeneity 
without changing treatment effect (RR=1.68, 95% CI:1.45 to 1.96, I2=26%). There were no 
subgroup differences by intervention type, risk of bias, IBS definition, IBS type, or study 
location. Subgroup differences by location were observed (p<0.01), due to one study from North 
America.69 On meta-regression there was no association between tr atment effect and percent 
females (p=0.38), but overall response was negatively associated with placebo response rate 
(p<0.01). Two studies63, 69 had a large impact on this association; after exclusion, the association 
was no longer significant (p=0.08). There was no significant publication bias (p=0.55). 
 
Efficacy of mind-body based therapy: Data on the efficacy of mind-body based for abdominal 
pain were analyzed from 14 papers containing 14 RCTs evaluating 1618 patients. Pooled 
analysis demonstrated benefit with intervention over placebo of borderline significance with high 
heterogeneity (SMD=0.29, 95% CI: -0.01 to 0.59, I2=78%, [Figure 3]) and very low confidence 
in estimates. Two studies43, 49 were large contributors to heterogeneity; exclusion reduced 
heterogeneity and changed the treatment effect to be statistically significant (SMD=0.27, 95% 
CI: 0.0002 to 0.53, I2=50%). There were no subgroup differences by intervention type, risk of 
bias, location, or study duration. There were subgroup differences by IBS definition (p<0.01, 
Supplementary Figure 7) and IBS severity with a larger treatment effect observed in non-severe 
IBS (p≤0.01, Supplementary Figure 8). On meta-regression, there were no significant 
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associations between treatment effect and percent fmales (p=0.57) or placebo response 
(p=0.45). Egger’s test showed asymmetry of the funnel plot (p=0.07) due to two studies.37, 43 
Data on efficacy of mind-body based therapy for overall response in IBS were available 
in 12 papers containing 12 RCTs evaluating 1539 patients. Mind-body based therapy was 
associated with benefit over placebo (RR=1.67, 95% CI: 1.13 to 2.49, I2=63%, [Supplementary 
Figure 9]),, corresponding to an NNT of 5 (95% CI: 3 to 25) with moderate heterogeneity and 
low confidence in estimates. Two studies55, 62 were large contributors to heterogeneity and 
exclusion reduced heterogeneity without changing treatment effect (RR=1.62, 95% CI: 1.26 to 
2.08, I2=27%). There were no subgroup differences by intervention type, risk of bias, location, or 
IBS severity. On meta-regression, there was no significa t association between treatment effect 
and percent females (p=0.78), but overall response was negatively associated with placebo 
response even after removing outliers (p<0.01). Egger’s test showed asymmetry of the funnel 
plot (p=0.10) due to one study.55  
Adverse events: Forty-three trials reported adverse events (AEs). AEs often overlapped with 
symptoms of IBS, particularly in dietary and herbal supplements. Headaches were commonly 
reported. Herbal studies that measured liver functio  chemistries did not report significant 
changes in laboratory parameters. Fourteen of 17 studies evaluating mind-body based therapies 
did not measure AEs; the few studies that did report d none. Energy-healing studies reported no 
AEs except for one study that reported mild musculoskeletal AEs. No studies reported serious 
AEs. 
DISCUSSION 
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This updated systematic review and meta-analysis of randomized placebo or sham-
controlled trials summarizes effects of CAM therapies on key patient-reported outcomes of 
abdominal pain and overall response and in IBS. Herbal and mind-body based therapies were the 
only CAM therapies for which there was evidence of benefit for abdominal pain. However, there 
was notable heterogeneity between studies even after excluding outliers. For mind-body based 
therapy, there was also evidence of publication bias or small study effects and subgroup analysis 
revealed differences by IBS severity with larger trea ment effects in non-severe IBS. Pooled 
analysis of body-based therapy, energy-healing therapy and dietary supplements demonstrated 
no significant benefit for abdominal pain with variable degrees of heterogeneity. 
For overall response, herbal, dietary and mind-body based therapies were associated with 
benefit over placebo or sham. There was no evidence of significant publication bias; however, 
moderate to high heterogeneity between studies was observed for all three therapies, which 
appeared to be driven by the presence of a few outliers. Among herbal therapy and mind-body 
based trials, meta-regression further revealed a neg tiv  association between treatment affect and 
placebo response, reaffirming the importance of measuring placebo responses when evaluating 
the efficacy of CAM in clinical IBS trials. Although a trend towards benefit with energy-healing 
therapy was observed, differences compared to placebo or sham were not statistically significant. 
There was no significant benefit with body-based therapies over placebo; however, moderate 
heterogeneity was noted that was not explained by su group analyses. 
Prior reviews have also demonstrated a benefit withthe mind-body based therapies, but 
these studies largely compared interventions to wait-list controls or usual care which may 
overestimate treatment responses.8, 85 Our findings demonstrate that even when limiting aalyses 
to studies designed with sham or placebo controls, mind-body therapies continue to demonstrate 
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evidence for efficacy for both abdominal pain and overall response with potential increased 
efficacy in patients with non-severe IBS.  
Not all studies reported AEs, and many reported AEsoverlapped with symptoms of IBS. 
No serious AEs were reported, suggesting that overall, CAM therapies demonstrate a reasonable 
safety profile in IBS.  
Major aspects that differentiate this systematic review and meta-analysis from prior 
reviews is the comprehensive coverage summarizing available data on various CAM therapies 
from 66 articles involving 6764 patients, extensive subgroup and sensitivity analyses to identify 
potential contributors to inconsistency or heterogeneity, detailed examination of study quality, 
separate assessment of abdominal pain as a patient-repor ed outcome and our focus on placebo or 
sham controlled trials. The placebo effect is directly correlated with the expectation and 
experience that the placebo delivers. Prior meta-analyses for specific CAM therapies have had 
variable comparison groups that may not represent an optimal ‘placebo’ control. We applied 
strict criteria used to define an acceptable placebo or sham. Only studies with a control arm 
deemed to be an adequately comparable experience with comparable expectations to the 
intervention were included. Many previously published meta-analyses on IBS have used controls 
including wait-lists, no therapy, or different modalities of therapy.8, 85 However, inadequate 
placebo controls may lead to a more favorable intervention response, particularly in an IBS 
patient population where high placebo responses are common. Additionally, our search strategy 
led to the inclusion of studies from around the world, which may make results more broadly 
generalizable. These aforementioned strengths enabl a more thorough and informed assessment 
of the efficacy of available CAM therapies for IBS.  
Our study does have some limitations. As expected, there was notable heterogeneity that 
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was not completely explained by subgroup analyses within each therapy type for either of the 
measured outcomes. However, in several cases, sensitivity analyses revealed sources of potential 
heterogeneity through the identification of outliers while subgroup analyses suggested 
differences due to patient characteristics and placebo response rates. Another limitation is some 
degree of reporting bias. Several potentially eligib e studies were excluded as the data were 
unusable for our means or unavailable despite contati g the corresponding authors. Only a 
handful of studies were rated as low risk of bias in every area for abdominal pain and overall 
response, and overall confidence in estimates low to very low (Table 2 and Supplementary Table 
1). In general, dietary and herbal therapies tended to be at lower risk of bias compared to other 
therapies, which is not unexpected given the relative ease of producing a comparable placebo 
and the feasibility of blinding participants. As reported by others,86 there are inherent limitations 
in the methodological quality of individual studies of CAM therapy. Lastly, there was 
incomplete capturing of potentially important factors such as IBS severity, which was not 
reported in many studies, and whether or not CAM was utilized as an adjunct to conventional 
therapies or after failed conventional therapy.  
Although the mechanisms by which CAM therapies confer benefit for symptoms of IBS 
are not fully understood, the CAM modalities covered in this study may target many of the 
mechanisms implicated in IBS pathophysiology including altered brain-gut connections, 
enteroendocrine abnormalities, altered motility, intestinal hypersensitivity and increased 
intestinal permeability.87 Benefit with mind-body based interventions such as cognitive 
behavioral therapy and hypnotherapy may occur via the brain-gut axis88 through targeting of 
psychological factors and central dysregulation critical to pain processing and perceptual 
responses. Mechanisms of action that have been proposed for acupuncture include pain 
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modulation and intestinal motility regulation;56 however, no significant treatment effects were 
observed in this review. Herbal and dietary interventions may potentially exert benefit as 
observed in this study through effects on visceral hypersensitivity, intestinal permeability, and 
smooth muscle contractility.19, 30, 33, 67, 84  
In conclusion, our findings add to the existing body of literature suggesting that mind-
body based, herbal and dietary therapies exhibit some potential in IBS. There is a continued need 
for novel evidence-based practices for the optimal nagement of IBS, regardless of whether 
treatments are CAM or traditional Western medicine. Therapy options should also align with 
patients’ willingness and preferences, who in many cases may be willing and interested in 
exploring CAM. CAM may also serve as a useful adjunct for patients who are refractory to 
traditional approaches. However, additional high quality RCTs are needed, particularly studies of 
adequate methodological rigor that have appropriately d signed placebo or sham controls and 
validated, clinically meaningful endpoints. It would be beneficial for future studies to adopt the 
FDA’s guidance on pharmaceutical treatments for IBS.13 Further work on CAM in IBS should be 
pursued to maximize therapeutic options, increase CAM awareness among clinicians, and 
respond to patients’ needs and experiences in IBS. It may be particularly worthwhile to focus 
future research efforts on herbal, dietary, and mind-body based therapies. 
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Table 1: Study Characteristics 
Study ID Location 
Outcome 
Intervention Control 
IBS Details Mean Age (SD) % Female 
Duration N  
AP OR Definition Type Severity CAM Placebo CAM Placebo 
Body-Based                           
Relaxation                         9 studies 
  Blanchard 1992 - Study 1 USA Likert CPSR PMR, thermal biofeedback, stress management at ention placebo S - - 43.3 43 90 60 8 weeks 20 
  Blanchard 1992 - Study 2 USA Likert CPSR PMR, thermal biofeedback, stress management at ention placebo S Any - 43.9 (13.1) 43,9 (13.6) 65.6 66.7 8 weeks 61 
  Craske 2011 - Relaxation USA BSS BSS PMR, stress management attention placebo II Any - 39.47 (13.5) 74.3 10 weeks 63 
  Fernandez 1998 - Relaxation Spain Likert Other PMR, stress management attention placebo Manning Any PP 47 49 66 66 10 weeks 44 
  Fernandez 2006 - Relaxation Spain Likert x PMR, stress management attention placebo S - - 48.1 (10.1) 70 6 weeks 10 
  Lahmann 2010 Germany Likert x functional relaxation EMC + counseling II Any - 49.7 (10.6) 47.9 (11.9) 72.5 60 5 weeks 80 
  Shinozaki 2010 Japan Other AR autogenic training diet discussions II Any Refr 32.8 (2.8) 30.3 (15.4) 54.5 50 8 weeks 21 
Other                             
  Attali 2013  France VAS x visceral osteopathy placebo manipulation III Any Refr 50 (2) 74.2 4 weeks 31 
  Grosjean 2017 France x Other micro-physiotherapy sham therapy S - - 51.5 (14.4) 55.6 (16.2) 64.5 60 4 weeks 61 
Dietary Supplement                           
Aloe Vera                          15 studies 
  Davis 2006 England IBS-SSS aloe vera placebo II Any Refr - - 74 81 4 weeks 58 
  Hutchings 2001 England GSRS x aloe vera placebo II Any Refr 46.0 (13.6) 47 (13.7) 76.4 76.4 5 months 110 
  Storsrud 2015 Sweden IBS-SSS aloe vera placebo III - - 43.9 (13.3) 44.2 (14.5) 72 77 4 weeks 68 
Other                             
  Azpiroz 2017 Spain, France Other x scFOS placebo III Any - 41.0 (11.1) 42.4 (10.6) 78 74 4 weeks 77 
  Chen 2015 China IBS-SSS x berberine hcl placebo III D - 37.4 36.1 72.9 69.4 8 weeks 132 
  Cremon 2017 Italy Likert x palmitoylethanolamide and polydatin placebo III Any - 37 (10.8) 40.4 (9.8) 62.1 44 12 weeks 54 
  Dale 2019 Norway IBS-SSS x cod protein hydrolysate placebo IV D, M - 42.7 (11.9) 45.1 (14.8) 92 73 6 weeks 31 
  Kamiya 2014 Japan GSRS biobran placebo III D, M - 48.8 (14.7) 49.6 (16.0) 52.6 45 4 weeks 39 
  Mosaffa-Jahromi 2016 Iran VAS Other enteric coated anise oil placebo III Any - *34.6 (9.7) 32.4 (7.2) 51.3 45 4 weeks 120 
  Saha 2007 India other x melatonin placebo II - Refr [27] [22] 33.3 33.3 8 weeks 18 
  Shin 2018 Korea Likert Other alkaline water placebo III D - 43.3 (14.4) 40.1 (15.7) 76.9 71.4 8 weeks 27 
  Trifan 2019 Romania Likert x XG+PPT+XOS placebo III D - 35.0 (7.8) 34.5 (8.1) 83 63 4 weeks 60 
  Van Tilburg 2014 USA IBS-SSS AR ginger placebo III - - - - - - 4 weeks 45 
  Wilson 2013 Canada Other x bovine IVG placebo II D - *46.9 (9.7) 47.8 (10.4) 58.1 71.4 6 weeks 45 
  Zhou 2019 USA IBS-SSS oral glutamine placebo III D - 32.4 (9.5) 30.9 (7.1) 68.5 71.2 8 weeks 115 
Energy-healing                           
Acupuncture                          8 studies 
  Anastasi 2009 USA Likert x acupuncture and moxibustion sham therapy II - - 47.1 34.3 64.3 66.7 4 weeks 29 
  Forbes 2005 England Likert Improve acupuncture sham therapy I, Manning Any - 43 44.4 59.3 71.9 12 weeks 59 
  Lembo 2009 - Augmented USA x AR acupuncture augmented interaction sham therapy II Any - 37.5 (14.6) 38.9 (14.1) 78 77 3 weeks 82 
  Lembo 2009 - Limited USA x AR acupuncture limited interaction sham therapy II Any - 37.5 (14.6) 38.9 (14.1) 78 77 3 weeks 71 
  Lowe 2017 Canada McGill Other acupuncture sham therapy I Any - 42 (15) 43 (15) 84 72 4 weeks 87 
  Park 2012 Korea BSS x korean hand acupuncture sham therapy III Any - 22.3 (3.2) 21.5 (2.7) 100 100 4 weeks 59 
Other                             
  Ma 2013 China GSRS x moxibustion placebo moxibustion III D - 26.7 25.4 77.3 76 4 weeks 150 
  Mak 2019 China Likert x electroacupuncture sham therapy III D - 50.85 (11.57) 50.83 (14.15) 50 55 10 weeks 80 
Herbal                           
Curcuma                          23 studies 
  Alt 2017 Malaysia IBS-SSS Improve curcuma, peppermint oil, caraway oil placebo III - - 44 (13) 47.5 (14.8) 70 68.1 8 weeks 90 
  Brinkhaus 2005 Germany VAS Improve curcuma, furmitory placebo S Any - *49.3 (12.0) 47.2 (11.7) 64.6 62 18 weeks 119 
  Portincasa 2016 Italy IBS-SSS Improve curcuma, fennel placebo III Any Mod 41.5 39.4 41 70.7 30 days 121 
Tong-Xie                             
  Chen 2018 China VAS AR tong-xie-yao-fang placebo III D - 35.4 (10.7) 32.7 (8.2) 48.8 61.3 3 weeks 160 
  Fan 2017 China Likert AR tong-xie placebo III D - 36.3 (0.7) 36.6 (0.7) 58 59 4 weeks 696 
  Leung 2006 Wales Likert AR tong-xie-yao-fang placebo II D - 45.4 (11.9) 43.6 (13.9) 48.3 55.9 8 weeks 119 
  Pan 2009 China Likert Nimodipine tong-xie-yao-fang placebo III D - 39.2 (13.4) 37.5 (15.6) 58.8 57.5 4 weeks 120 
  Wang 2006 China x Other tong-xie-ning placebo II D - 37.1 (10.4) 36.9 (8.9) 44.8 64.3 3 weeks 60 
Other                             
  Acosta 2016 USA VAS x diakenchuto placebo III Any - 39.5 (2.7) 43 (2.6) 100 100 2 weeks 40 
  Bensoussan 1998 Australia BSS chinese herbal medicine placebo I Any - *47.5 (14.2) 45 (13.9) 68.6 63 16 weeks 116 
  Bensoussan 2015 Australia x AR chinese herbal medicine placebo III C - 48.2 (1.25) 48.9 (1.5) 93.4 92.2 16 weeks 125 
  Kazemian 2017 Iran IBS-SSS x boswellia caterii placebo III Any Mild-Mod 36.3 (10.9) 41.3 (12.6) 44.6 27.2 12 weeks 42 
  Ko 2013 Korea VAS AR korean herbal medicine plus probiotic placebo III D - 47.5 (13.6) 47.5 (16.0) 37.5 23.5 8 weeks 26 
  Lee 2019 Korea Likert Improve samryungbaekchul-san placebo III D - 38.05 (15.27) 45.2 (13.56) 20 45 8 weeks 36 
  Madisch 2005 Germany VAS Other BCT and STW placebo S Any - *46.4 (12.1) 46.1 (10.4) 63.1 57.7 4 weeks 208 
  Merat 2010 Iran x Other peppermint oil placebo II Any - 35 (13) 37 (11) 84.8 63 8 weeks 90 
  Peckham 2014 England IBS-SSS x homeopathic treatment supportive listening III - Mild 48.2 (13.5) 42.5 (16.2) 100 78 26 weeks 76 
  Saito 2010 USA BSS AR st john wort placebo II Any - [43] [42] 86 86 12 weeks 70 
  Sallon 2002 Isreal Likert Other padma lax placebo I C - 47.9 (2.1) 46.3 (2.9) 71 74 12 weeks 80 
  Su 2013 China x Nimodipine sishen wen placebo III D - 38 (12) 37 (12) 55.8 59.2 4 weeks 240 
  Tang 2018 China IBS-SSS AR chang' an I recipie placebo III D Any 42.9 (13.8) 42.5 (14.0) 37.4 38.3 8 weeks 216 
  Vejdani 2006 Iran x Other carmint placebo II Any - 31 (10.8) 46 (12) 35.7 50 8 weeks 32 
  Yadav 1989 India x Other ayurvedic herbal compound placebo S Any - 29.2 27.7 12.3 11.5 6 weeks 109 
Mind-Body Based                           
CBT                          16 studies 
  Blanchard 2007 USA McGill x group CBT psychodeducational support II Any Mod-Sev 48.1 (13.7) 51.5 (11.3) 77.1 92.5 2 weeks 82 
  Craske 2011 - CBT USA BSS CBT with interoceptive exposure attention placebo II Any - 39.47 (13.5) 74.3 10 weeks 69 
  Drossman 2003 USA, Canada McGill Other CBT attention, education I Any Mod-Sev 37.9 (11.8) 36.1 (11.8) 100 100 12 weeks 215 
  Hunt 2009 USA GSRS x CBT attention placebo SI - - 39 (10) 38 (12) 76 85 6 weeks 54 
  Jang 2014 Korea BSS x CBT education, attention placebo III Any - 21.9 (1.9) 21.2 (2.3) 100 100 8 weeks 81 
  Lackner 2018 USA IBS-SSS Other CBT education, group discussion III Any Mod-Sev *41.0 (14.5) 42.2 (15.4) 81.1 79.2 10 weeks 436 
  Ljotsson 2010 Sweden Likert CPSR CBT online support group III Any - 36.4 (10.1) 32.8 (8.6) 83.3 86 10 weeks 86 
  Payne 1995 USA x CPSR CBT self-help support group I Any - 39.7 (13.1) 44 (9.3) 83.3 91.7 8 weeks 24 
  Tkachuk 2003 Canada Other CPSR group CBT telephone attention control I Any - 39.5 96 9 weeks 28 
Hypnotherapy                             
  Filk 2019 Netherlands IBS-SSS AR hypnotherapy 
supportive educational 
therapy 
III - - 37.3 (13.2) 34.5 (12.5) 77 89 
12 weeks 342 
  Lindfors 2012 - Study 1 Sweden Likert Improve gut-directed hypnotherapy supportive listening II Any Refr 43 41 77.8 80 12 weeks 90 
  Moser 2013 Austria x Other gut-directed hypnotherapy supportive listening III Any Refr 40.4 (14.7) 50.8 (13.9) 80.4 78.7 12 weeks 100 
  Simren 2004 Sweden Other Other gut-directed hypnotherapy supportive listening II Any Refr 42.4 (13.9) 41.5 (3.8) 64.3 71.4 12 weeks 28 
Other                             
  Fernandez 1998 - Behavior Spain Likert Other contingency management attention placebo Manning Any PP 40 49 75 66 10 weeks 46 
  Fernandez 2006 - Behavior Spain Likert x contingency management attention placebo - - - 48.1 (10.1) 70 6 weeks 10 
  Gaylord 2011 USA IBS-SSS mindfullness support group, education II - - 44.7 (12.6) 40.9 (14.7) 100 100 8 weeks 75 
Note: USA = United States, AP = abdominal pain, OR = overall response, x = not studied, BSS = Bowel Symptom Score, IBS-SSS = IBS Symptom Severity Score, CPSR = Composite Primary Symptoms Reduction score, AR = adequate relief, VAS = Visual Analog Scale, GSRS = 
Gastrointestinal Symptom Rating Scale, CBT = cognitive behavioral therapy, scFOS = short-cahin fructooligosaccharides, PMR = progressive muscle relaxation, XG+PPT+XOS = xyloglucan, pea protein, tannins from grapeseed, xylo-oligosaccharides, BCT = bitter candyfruit,  STW = 
iberogast, IVG = intravenous globin, - = not specified by article, * = combined mean (standard deviation) from multiple interventions, ** = mean age and standard deviation not reported, numbers listed in age groups, S = symptoms without organic disease, II = Rome II Criteria, III = Rome III 
Criteria, IV = Rome IV Criteria, SI = patient self-identified, Mod = moderate, Sev = severe, Refr = refractory, PP = poor prognosis, [#] = median age
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Ser.  Ser. Ser. Ser. No Ser. Low 0.13 (-0.26-0.51) 
6 6 Energy Healing 232 232 V. Ser. No Ser. No Ser. Ser. No Ser. Low 0.21 (-0.20-0.61) 
17 17 Herbal 1206 1078 Ser Ser. Ser. No Ser. Ser. Low 0.47 (0.20-0.75) 
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44 56   3033 2340      Low RR NNT 
5 6 Body-Based 145 125 V. Ser. No Ser. No Ser. Ser. No Ser. Low 1.32 (0.89- 1.95 8 (3-23) 
7 7 
Dietary 
Supplements 225 207 
Ser.   No Ser. No Ser. No Ser. No Ser. Moderate 1.95 (1.02-3.73) 4 (2-189) 
3 4 Energy Healing 151 148 V. Ser. No Ser. No Ser. Ser. No Ser. Low 1.32 (0.99- 1.76) 10 (4-303) 
20 20 Herbal 1506 1327 Ser. No Ser. No Ser. No Ser. Ser. Moderate 1.57 (1.31-1.88) 5 (4-9) 
12 12 
Mind-Body 
Based 1006 533 
V. Ser. No Ser. No Ser. No Ser. Ser. Low 1.67 (1.13-2.49) 5 (3-25) 
Note: totals of articles and RCTs do not amount to the sum of the included studies as several articles include multiple RCTs from different CAM categories. Body-Based = relaxation, etc. Dietary 






Supplementary Figure 1: Forest plot of studies of body-based therapy vs placebo or sham with 
effect on abdominal pain 
 
Supplementary Figure 2: Forest plot of studies of body-based therapy vs. placebo or sham 
with effect on overall response 
 
  
Supplementary Figure 3: Forest plot of studies of dietary supplement vs placebo or sham with 
effect on abdominal pain by type of intervention (between group p-value = 0.068) 
 
Supplementary Figure 4: Forest plot of studies of dietary supplement vs placebo or sham with 




Supplementary Figure 5: Forest plot of studies of energy-healing vs placebo or sham with 
effect on abdominal pain by type of intervention (between-group p-value = 0.81) 
 
Supplementary Figure 6: Forest plot of studies of energy-healing vs. placebo or sham with 
effect on overall response 
 
Supplementary Figure 7: Forest plot of studies of mind-body based therapy vs placebo or 
sham with effect on abdominal pain by IBS definition (between-group p-value < 0.001) 
 
Supplementary Figure 8: Forest plot of studies of mind-body based therapy vs placebo or 




Supplementary Figure 9: Forest plot of studies of mind-body based therapy vs placebo or 
sham with effect on overall response by intervention (between group p-value = 0.87) 
 
 
Study Eligibility: The review was limited to trials with a minimum duration of two weeks of 
therapy. First-period data from cross-over trials were also eligible. Studies investigating other 
organic gastrointestinal conditions such as inflammatory bowel disease, microscopic colitis, and 
celiac disease and trials without an appropriate placebo or sham control group were excluded. 
The diagnosis of IBS was determined using any definition provided by the study including 
symptom-based diagnostic criteria. 
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Supplementary Table 2: Subgroup Analyses 














Body-Based Risk of Bias 
Moderate 3 145 1.57 (0.83; 2.98) 
0.36 
High 3 125 1.10 (0.72; 1.67) 
Dietary      
Supplement 
Intervention 
Aloe Vera 2 126 1.69 (1.05; 2.73) 
0.67 
Other 5 306 2.13 (0.84; 5.41) 
Risk of Bias 
Low 5 272 1.86 (1.39; 2.48) 
0.76 




Curcuma 3 330 1.72 (1.11; 2.65) 
0.8 Tong-Xie 5 1155 1.44 (1.01; 2.05) 
Other 12 1348 1.61 (1.25; 2.07) 
Risk of Bias 
Low 9 950 1.37 (1.04; 1.79) 
0.051 
High  10 1363 1.91 (1.56; 2.33) 
Location 
Europe 4 567 1.41 (0.95; 2.10) 
0.6 Asia 13 1955 1.73 (1.44; 2.06) 
Australia 2 241 1.53 (1.10; 2.12) 
IBS 
Definition 
Diagnostic Criteria 17 2397 1.58 (1.29; 1.95) 
0.81 
Not Specified 3 436 1.51 (1.08; 2.11) 
IBS Type 
C 2 105 1.86 (0.96; 3.59) 
0.8 D/M 9 1673 1.50 (1.20; 1.87) 
Unspecified 9 955 1.62 (1.16; 2.24) 
Study 
Duration 
<8 weeks 8 1714 1.70 (1.37; 2.11) 
0.37 
8+ weeks 12 1119 1.45 (1.10; 1.92) 
Mind-Body         
Based 
Intervention 
CBT 6 858 1.85 (0.91; 3.75) 
0.87 Hypnotherapy 4 560 1.67 (0.82; 3.38) 
Other 2 131 1.50 (1.03; 2.20) 
Risk of Bias 
Moderate 2 505 1.23 (0.97; 1.55) 
0.12 
High 10 1034 1.87 (1.17; 2.99) 
Location 
North America 6 847 1.45 (1.11; 1.90) 
0.39 
Europe 6 692 2.09 (0.94; 4.62) 
IBS Severity 
Unspecified 6 624 1.95 (0.96; 3.96) 
0.55 









Body-Based Risk of Bias 
Moderate 3 115 -0.11 (-1.21; 0.99) 
0.7 
High 5 193 0.01 (-0.45; 0.46) 
Dietary      
Supplements 
Intervention 
Aloe Vera 3 222 -0.22 (-0.65; 0.22) 
0.68 
Other 12 717 0.22 (-0.25; 0.69) 
Risk of Bias 
Low 8 444 0.06 (-0.35; 0.47) 
0.79 
High 6 477 0.17 (-0.84; 1.18) 
Location 
North America 3 204 0.50 (-2.89; 3.90) 
0.068 Europe 7 444 -0.17 (-0.47; -0.13) 
Asia 5 291 0.33 (-0.19; 0.85) 
IBS Type 
D/M 7 449 0.18 (-0.65; 1.01) 
0.77 
Unspecified 8 490 0.07 (-0.33; 0.46) 
IBS Severity Unspecified 12 762 0.19 (-0.28; 0.66) 0.15 
Severe 3 177 -0.20 (-0.96; 0.55) 
Study 
Duration 
<8 weeks 9 483 -0.12 (-0.48; 0.23) 
0.082 




Acupuncture 4 234 0.20 (-0.62; 1.01) 
0.81 
Other 2 230 0.26 (-1.30; 1.83) 
Risk of Bias 
Moderate 3 289 0.17 (-0.38; 0.73) 
0.71 
High 3 175 0.31 (-1.16; 1.77) 
Herbal 
Intervention 
Curcuma 3 313 0.62 (-0.95; 2.19) 
0.52 Tong-Xie 4 1092 0.23 (-0.54; 0.99) 
Other 10 879 0.54 (0.14; 0.93) 
Risk of Bias 
Low 8 810 0.41 (-0.08; 0.90) 
0.45 Moderate 2 157 0.08 (-5.88; 6.04)  
High 7 1317 0.63 (0.22; 1.03) 
Study 
Location 
North America 2 110  -0.09 (-8.54; 8.35) 
0.67 Europe 5 624 0.42 (-0.12; 0.96) 
Asia 9 1434 0.60 (0.20; 1.00) 
IBS 
Definition 
Diagnostic Criteria 15 1972 0.49 (0.18; 0.79) 
0.74 
Not Specified 2 312  0.34 (-4.95; 5.63) 
IBS Type 
D/M 7 1360 0.35 (-0.04; 0.74) 
0.71 
Unspecified 9 863 0.57 (0.07; 1.07) 
Study 
Duration 
<8 weeks 6 1336 0.50 (0.04; 0.96) 
0.85 
8+ weeks 11 948 0.45 (0.04; 0.86) 
Mind-Body        
Based 
Intervention 
CBT 8 1050 0.31 (-0.12; 0.75) 
0.58 Hypnotherapy 3 460 0.07 (-0.99; 1.12) 
Other 3 108 0.48 (-1.05; 2.01) 
Risk of Bias 
Moderate 2 505 -0.02 (-4.07; 4.03) 
0.31 
High 12 1113 0.34 (0.01; 0.66) 
Location 
North America 7 959 0.24 (-0.24; 0.72) 
0.99 
Europe 6 578 0.24 (-0.32; 0.80) 
IBS 
Definition 
Diagnostic Criteria 12 1554 0.17 (-0.07; 0.41) 
<0.001 
Not Specified 2 64 1.30 (1.07; 1.52) 
IBS Severity 
Unspecified 8 744 0.56 (0.21; 0.91) 
<0.001 
Severe 6 874 -0.07 (-0.38; 0.24) 
Study 
Duration 
<8 weeks 3 146 0.74 (-1.39; 2.87) 
0.29 
8+ weeks 11 1472 0.20 (-0.06; 0.46) 
 
